These metabolic shifts are pivotal in the development of drug resistance because they enable cancer cells to maintain oncogenic signalling pathways and resist apoptosis, thereby rendering traditional HER2 inhibitors ineffective. This evidence concerns the gene ERBB2 and cancer.